| abstract |
H:\rbr\Inter n\NRPortbl\DCC\RBR\15809743I.doex-9/10/2017 Abstract The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1 (4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl) 5 trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1 methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)- isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3 d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a 10 pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor. WO 2015/097622 PCT/1B2014/067141 Figure 1 Inhibition .. . ...' .. . . .. . . CL' CompoundC (uM) |